PTC Therapeutics Inc (NASDAQ: PTCT) is 3.23% higher on its value in year-to-date trading and has touched a low of $24.00 and a high of $58.38 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PTCT stock was last observed hovering at around $50.96 in the last trading session, with the day’s loss setting it -4.36%.
Currently trading at $46.60, the stock is -13.87% and -8.76% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.88 million and changing -8.56% at the moment leaves the stock 12.19% off its SMA200. PTCT registered 60.19% gain for a year compared to 6-month gain of 24.07%. The firm has a 50-day simple moving average (SMA 50) of $51.0764 and a 200-day simple moving average (SMA200) of $41.5353.
The stock witnessed a -11.86% loss in the last 1 month and extending the period to 3 months gives it a 3.03%, and is -17.19% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.27% over the week and 4.93% over the month.
PTC Therapeutics Inc (PTCT) has around 939 employees, a market worth around $3.68B and $806.78M in sales. Profit margin for the company is -45.03%. Distance from 52-week low is 94.21% and -20.18% from its 52-week high.
with sales reaching $436.89M over the same period.The EPS is expected to grow by 18.36% this year, but quarterly earnings will post 16.79% year-over-year. Quarterly sales are estimated to grow 107.92% in year-over-year returns.
PTC Therapeutics Inc (PTCT) Top Institutional Holders
328.0 institutions hold shares in PTC Therapeutics Inc (PTCT), with institutional investors hold 102.44% of the company’s shares. The shares outstanding are 77.70M, and float is at 76.82M with Short Float at 5.60%. Institutions hold 99.94% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 8.97 million shares valued at $274.42 million. The investor’s holdings represent 11.731% of the PTCT Shares outstanding. As of 2024-06-30, the second largest holder is WELLINGTON MANAGEMENT GROUP LLP with 8.21 million shares valued at $251.02 million to account for 10.6987 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.77 million shares representing 10.1299% and valued at over $237.67 million, while RTW INVESTMENTS, LP holds 9.6359 of the shares totaling 7.39 million with a market value of $226.08 million.
PTC Therapeutics Inc (PTCT) Insider Activity
The most recent transaction is an insider sale by Pauwels Eric, the company’s CHIEF BUSINESS OFFICER. SEC filings show that Pauwels Eric sold 6,762 shares of the company’s common stock on Mar 17 ’25 at a price of $56.80 per share for a total of $0.38 million. Following the sale, the insider now owns 72640.0 shares.
PTC Therapeutics Inc disclosed in a document filed with the SEC on Mar 14 ’25 that Pauwels Eric (CHIEF BUSINESS OFFICER) sold a total of 4,458 shares of the company’s common stock. The trade occurred on Mar 14 ’25 and was made at $55.19 per share for $0.25 million. Following the transaction, the insider now directly holds 79402.0 shares of the PTCT stock.
Still, SEC filings show that on Mar 13 ’25, Okey Stephanie (Director) disposed off 5,000 shares at an average price of $54.00 for $0.27 million. The insider now directly holds 8,867 shares of PTC Therapeutics Inc (PTCT).
